Long COVID Symptomatology After 12 Months and Its Impact on Quality of Life According to Initial Coronavirus Disease 2019 Disease Severity

  • Aurélie Fischer
    Deep Digital Phenotyping Research Unit, Department of Population Health, Luxembourg Institute of Health, Strassen , Luxembourg
  • Lu Zhang
    Bioinformatics Platform, Luxembourg Institute of Health , Strassen , Luxembourg
  • Abir Elbéji
    Deep Digital Phenotyping Research Unit, Department of Population Health, Luxembourg Institute of Health, Strassen , Luxembourg
  • Paul Wilmes
    Luxembourg Center for Systems Biomedicine, University of Luxembourg, Belvaux , Luxembourg
  • Pauline Oustric
    Association “Après J20” , Lucé , France
  • Therese Staub
    Service National des Maladies Infectieuses, Centre Hospitalier de Luxembourg , Luxembourg , Luxembourg
  • Petr V Nazarov
    Bioinformatics Platform, Luxembourg Institute of Health , Strassen , Luxembourg
  • Markus Ollert
    Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette , Luxembourg
  • Guy Fagherazzi
    Deep Digital Phenotyping Research Unit, Department of Population Health, Luxembourg Institute of Health, Strassen , Luxembourg

書誌事項

公開日
2022-08-01
権利情報
  • https://creativecommons.org/licenses/by/4.0/
DOI
  • 10.1093/ofid/ofac397
公開者
Oxford University Press (OUP)

説明

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>“Long COVID” is characterized by a variety of symptoms and an important burden for affected people. Our objective was to describe long COVID symptomatology according to initial coronavirus disease 2019 (COVID-19) severity.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Predi-COVID cohort study participants, recruited at the time of acute COVID-19 infection, completed a detailed 12-month symptom and quality of life questionnaire. Frequencies and co-occurrences of symptoms were assessed.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Among the 289 participants who fully completed the 12-month questionnaire, 59.5% reported at least 1 symptom, with a median of 6 symptoms. Participants with an initial moderate or severe acute illness declared more frequently 1 or more symptoms (82.6% vs 38.6%, P &lt; .001) and had on average 6.8 more symptoms (95% confidence interval, 4.18–9.38) than initially asymptomatic participants who developed symptoms after the acute infection. Overall, 12.5% of the participants could not envisage coping with their symptoms in the long term. Frequently reported symptoms, such as neurological and cardiovascular symptoms, but also less frequent ones such as gastrointestinal symptoms, tended to cluster.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Frequencies and burden of symptoms present 12 months after acute COVID-19 infection increased with the severity of the acute illness. Long COVID likely consists of multiple subcategories rather than a single entity. This work will contribute to the better understanding of long COVID and to the definition of precision health strategies.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical Trials Registration</jats:title> <jats:p>NCT04380987.</jats:p> </jats:sec>

収録刊行物

被引用文献 (3)*注記

もっと見る

問題の指摘

ページトップへ